1-[(1-benzyl-1H-tetrazol-5-yl)(4-morpholin-4-ylphenyl)methyl]-4-cyclobutyl-1,4-diazepane | 1177251-19-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 恶嗪烷类
• 英文名称: 1-[(1-benzyl-1H-tetrazol-5-yl)(4-morpholin-4-ylphenyl)methyl]-4-cyclobutyl-1,4-diazepane
• 英文别名: 4-(4-((1-benzyl-1H-tetrazol-5-yl)(4-cyclobutyl-1,4-diazepan-1-yl)methyl)phenyl)morpholine；4-[4-[(1-benzyltetrazol-5-yl)-(4-cyclobutyl-1,4-diazepan-1-yl)methyl]phenyl]morpholine
• CAS: 1177251-19-2
• 化学式: C₂₈H₃₇N₇O
• 分子量: 487.648
• InChiKey: WKYCTQVNRAEEPL-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.6
• 重原子数：
  36
• 可旋转键数：
  7
• 环数：
  6.0
• sp3杂化的碳原子比例：
  0.54
• 拓扑面积：
  62.6
• 氢给体数：
  0
• 氢受体数：
  7

反应信息

• 作为产物：
  描述：

  1-cyclobutyl-1,4-diazepane 、 4-(4-吗啉)苯甲醛 、 苄异腈 在 叠氮基三甲基硅烷 作用下， 以 甲醇 为溶剂， 反应 18.0h， 生成 1-[(1-benzyl-1H-tetrazol-5-yl)(4-morpholin-4-ylphenyl)methyl]-4-cyclobutyl-1,4-diazepane
  参考文献：
  名称：

  Discovery of substituted benzyl tetrazoles as histamine H3 receptor antagonists

  摘要：

  A series of potent and subtype selective H3 receptor antagonists containing a novel tetrazole core and diamine motif is reported. A one-pot multi-component Ugi reaction was utilised to rapidly develop the structure-activity relationships (SAR) of these compounds. Optimisation for liver microsome stability (t(1/2) >60 min), minimal CYP inhibition (IC(50) >50 mu M) and high cell permeability (Caco-2 P(app) >20 x 10 (6) cm/s) identified several compounds with drug-like properties. (C) 2010 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2010.07.009

文献信息

• [EN] DIAZEPANES AS HISTAMINE H3 RECEPTOR ANTAGONISTS<br/>[FR] DIAZÉPANES, ANTAGONISTES DU RÉCEPTEUR H3 DE L'HISTAMINE
  申请人：EVOTEC NEUROSCIENCES GMBH

  公开号：WO2009095394A1

  公开（公告）日：2009-08-06

  The invention relates to compounds of formula (I) wherein R1 to R8 and X1, X2 have the meaning as cited in the description and the claims. Said compounds are useful as Histamine H3 receptor antagonists. The invention also relates to pharmaceutical compositions, the preparation of such compounds as well as the production and use as medicament.

  该发明涉及式(I)的化合物，其中R1至R8和X1、X2的含义如描述和权利要求中所述。所述化合物可用作组胺H3受体拮抗剂。该发明还涉及制药组合物，制备此类化合物以及作为药物的生产和使用。
• Discovery of substituted benzyl tetrazoles as histamine H3 receptor antagonists
  作者：Adam J. Davenport、Christopher C. Stimson、Massimo Corsi、Darshan Vaidya、Edward Glenn、Timothy D. Jones、Sarah Bailey、Mark J. Gemkow、Ulrike Fritz、David J. Hallett

  DOI：10.1016/j.bmcl.2010.07.009

  日期：2010.9

  A series of potent and subtype selective H3 receptor antagonists containing a novel tetrazole core and diamine motif is reported. A one-pot multi-component Ugi reaction was utilised to rapidly develop the structure-activity relationships (SAR) of these compounds. Optimisation for liver microsome stability (t(1/2) >60 min), minimal CYP inhibition (IC(50) >50 mu M) and high cell permeability (Caco-2 P(app) >20 x 10 (6) cm/s) identified several compounds with drug-like properties. (C) 2010 Elsevier Ltd. All rights reserved.